Evaluation of safety and efficacy of Tirofiban injection for treating acute ischemic stroke beyond standard time window
Abstract To evaluate the safety and efficacy of tirofiban in the treatment of acute ischemic stroke (AIS). Clinical data of 152 AIS patients with small vessel occlusion admitted in 2023 were retrospectively analyzed. These patients did not receive intravenous thrombolysis and endovascular treatment...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-11882-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849235400651964416 |
|---|---|
| author | Qian Yang Qiaofeng He Xinfa Mao Weibing Fan Xin Luo |
| author_facet | Qian Yang Qiaofeng He Xinfa Mao Weibing Fan Xin Luo |
| author_sort | Qian Yang |
| collection | DOAJ |
| description | Abstract To evaluate the safety and efficacy of tirofiban in the treatment of acute ischemic stroke (AIS). Clinical data of 152 AIS patients with small vessel occlusion admitted in 2023 were retrospectively analyzed. These patients did not receive intravenous thrombolysis and endovascular treatment within 72 h of onset. Patients were divided into two groups (n = 76 each group): a dual antiplatelet group (aspirin + clopidogrel for 14 days, followed by aspirin alone) and a tirofiban group (dual antiplatelet therapy plus tirofiban). Neurological deficits and functional outcomes were assessed before treatment, on day 7, and day 90. Serum hs-CRP and IL-6 levels were measured prior to treatment and on day 7. Symptom aggravation, symptomatic bleeding, and mortality within 90 days were also recorded. Baseline characteristics of the two groups were comparable. Tirofiban treatment significantly improved mRS scores from baseline to day 7 (t = 5.94, p < 0.001) and day 90 (t = 5.67, p < 0.001) (F = 53.13, p < 0.001), with improvements persisting after adjusting for baseline scores (F = 32.56, p < 0.001). Moreover, tirofiban treatment significantly reduced NIHSS scores at days 7 (mean difference = − 0.97 (95% CI: − 1.53, − 0.41); t = 3.57, p < 0.001) and 90 (mean difference = − 0.82 (95% CI: − 1.29, − 0.34); t = 3.97, p < 0.001) and increased Barthel Index scores at days 7 (mean difference = 9.8 (95% CI: 4.3, 15.3); t = − 3.14, p = 0.002) and 90 (mean difference = 11.7 (95% CI: 6.2, 17.2); t = − 4.41, p < 0.001), indicating greater functional independence. No significant differences were observed between the two groups in inflammatory markers (hs-CRP and IL-6), intracranial hemorrhage, or mortality. However, there was a trend toward a higher rate of deterioration in the dual antiplatelet group (13.4% vs. 5.6%). Tirofiban combined with conventional treatment significantly improves neurological deficits and disease outcomes in AIS patients without increasing the risk of bleeding and mortality. |
| format | Article |
| id | doaj-art-c04fe136f0a0470a90e5f15818cfdd44 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-c04fe136f0a0470a90e5f15818cfdd442025-08-20T04:02:46ZengNature PortfolioScientific Reports2045-23222025-07-0115111010.1038/s41598-025-11882-2Evaluation of safety and efficacy of Tirofiban injection for treating acute ischemic stroke beyond standard time windowQian Yang0Qiaofeng He1Xinfa Mao2Weibing Fan3Xin Luo4Department of Neurology, The Third Hospital of ChangshaDepartment of Neurology, The Third Hospital of ChangshaDepartment of Neurology, The Third Hospital of ChangshaDepartment of Neurology, The Third Hospital of ChangshaDepartment of Neurology, The Third Hospital of ChangshaAbstract To evaluate the safety and efficacy of tirofiban in the treatment of acute ischemic stroke (AIS). Clinical data of 152 AIS patients with small vessel occlusion admitted in 2023 were retrospectively analyzed. These patients did not receive intravenous thrombolysis and endovascular treatment within 72 h of onset. Patients were divided into two groups (n = 76 each group): a dual antiplatelet group (aspirin + clopidogrel for 14 days, followed by aspirin alone) and a tirofiban group (dual antiplatelet therapy plus tirofiban). Neurological deficits and functional outcomes were assessed before treatment, on day 7, and day 90. Serum hs-CRP and IL-6 levels were measured prior to treatment and on day 7. Symptom aggravation, symptomatic bleeding, and mortality within 90 days were also recorded. Baseline characteristics of the two groups were comparable. Tirofiban treatment significantly improved mRS scores from baseline to day 7 (t = 5.94, p < 0.001) and day 90 (t = 5.67, p < 0.001) (F = 53.13, p < 0.001), with improvements persisting after adjusting for baseline scores (F = 32.56, p < 0.001). Moreover, tirofiban treatment significantly reduced NIHSS scores at days 7 (mean difference = − 0.97 (95% CI: − 1.53, − 0.41); t = 3.57, p < 0.001) and 90 (mean difference = − 0.82 (95% CI: − 1.29, − 0.34); t = 3.97, p < 0.001) and increased Barthel Index scores at days 7 (mean difference = 9.8 (95% CI: 4.3, 15.3); t = − 3.14, p = 0.002) and 90 (mean difference = 11.7 (95% CI: 6.2, 17.2); t = − 4.41, p < 0.001), indicating greater functional independence. No significant differences were observed between the two groups in inflammatory markers (hs-CRP and IL-6), intracranial hemorrhage, or mortality. However, there was a trend toward a higher rate of deterioration in the dual antiplatelet group (13.4% vs. 5.6%). Tirofiban combined with conventional treatment significantly improves neurological deficits and disease outcomes in AIS patients without increasing the risk of bleeding and mortality.https://doi.org/10.1038/s41598-025-11882-2Acute ischemic strokeTirofibanStandard time windowMortalityCerebral hemorrhage |
| spellingShingle | Qian Yang Qiaofeng He Xinfa Mao Weibing Fan Xin Luo Evaluation of safety and efficacy of Tirofiban injection for treating acute ischemic stroke beyond standard time window Scientific Reports Acute ischemic stroke Tirofiban Standard time window Mortality Cerebral hemorrhage |
| title | Evaluation of safety and efficacy of Tirofiban injection for treating acute ischemic stroke beyond standard time window |
| title_full | Evaluation of safety and efficacy of Tirofiban injection for treating acute ischemic stroke beyond standard time window |
| title_fullStr | Evaluation of safety and efficacy of Tirofiban injection for treating acute ischemic stroke beyond standard time window |
| title_full_unstemmed | Evaluation of safety and efficacy of Tirofiban injection for treating acute ischemic stroke beyond standard time window |
| title_short | Evaluation of safety and efficacy of Tirofiban injection for treating acute ischemic stroke beyond standard time window |
| title_sort | evaluation of safety and efficacy of tirofiban injection for treating acute ischemic stroke beyond standard time window |
| topic | Acute ischemic stroke Tirofiban Standard time window Mortality Cerebral hemorrhage |
| url | https://doi.org/10.1038/s41598-025-11882-2 |
| work_keys_str_mv | AT qianyang evaluationofsafetyandefficacyoftirofibaninjectionfortreatingacuteischemicstrokebeyondstandardtimewindow AT qiaofenghe evaluationofsafetyandefficacyoftirofibaninjectionfortreatingacuteischemicstrokebeyondstandardtimewindow AT xinfamao evaluationofsafetyandefficacyoftirofibaninjectionfortreatingacuteischemicstrokebeyondstandardtimewindow AT weibingfan evaluationofsafetyandefficacyoftirofibaninjectionfortreatingacuteischemicstrokebeyondstandardtimewindow AT xinluo evaluationofsafetyandefficacyoftirofibaninjectionfortreatingacuteischemicstrokebeyondstandardtimewindow |